A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Clinical trial NCT04542057 · COMPLETED
Trial details
- NCT number
- NCT04542057
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-22
- Primary completion
- 2022-05-03
- Enrollment
- 790
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.